LCID
Lucid Group, Inc.
LCID has the edge over LEN overall, supported by stronger modeled upside and stronger valuation.
LEN
Lennar Corporation
LEN trails on the overall score without a compensating advantage in the available component scores.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Strong |
LEN's balance sheet is currently strong, and its revenue, profitability and cash flow are stable.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
LEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.7x | $35.62 | -57% |
| Fair | 10x | $53.28 | -36% |
| Expensive | 12x | $64.56 | -23% |
| Current | 16x | $83.58 | — |
| Forward | 18x | $83.58 | — |
Historical ranges are pointers, not guarantees.
LEN's PE is in its expensive range at 16x. Analysts expect earnings to fall, which would put today's price at 18x next year's earnings.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LEN Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Decline | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect LEN's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
LEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.68 | -11% |
| Q3 2026 | $5.28 | -48% |
| Q2 2026 | $6.38 | -46% |
| Q1 2026 | $6.95 | -48% |
| Q4 2025 | $7.98 | -43% |
| Q3 2025 | $10.09 | -31% |
| Q2 2025 | $11.92 | -16% |
| Q1 2025 | $13.45 | -2.5% |
| Q4 2024 | $13.98 | +5.2% |
LEN has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over LEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
LEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8B | -8.7% |
| Q2 2026 | $7.9B | -5.2% |
| Q1 2026 | $6.6B | -13% |
| Q4 2025 | $9.4B | -5.8% |
| Q3 2025 | $8.8B | -6.4% |
| Q2 2025 | $8.4B | -4.4% |
| Q1 2025 | $7.6B | +4.4% |
| Q4 2024 | $9.9B | -9.3% |
LEN's revenue has slid since its 2023 peak: $8B last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -2.2 points |
| Q2 2026 | 5% | -2.5 points |
| Q1 2026 | 3.3% | -5.8 points |
| Q4 2025 | 6.9% | -7.8 points |
| Q3 2025 | 7.9% | -5.7 points |
| Q2 2025 | 7.5% | -6.4 points |
| Q1 2025 | 9.1% | -3.2 points |
| Q4 2024 | 15% | -1.6 points |
LEN has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
LEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$96.3M | +$94.5M |
| Q2 2026 | -$303.2M | +$807M |
| Q1 2026 | -$463.5M | -$118.4M |
| Q4 2025 | $1.7B | +79% |
| Q3 2025 | -$190.8M | -124% |
| Q2 2025 | -$1.1B | -647% |
| Q1 2025 | -$345.1M | -217% |
| Q4 2024 | $933.1M | -63% |
LEN has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
LEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -3M shares |
| 1 year | -7% | -17.8M shares |
| 3 years | -19% | -54.4M shares |
| 5 years | -25% | -79.7M shares |
| Available history | -28% | -91.2M shares |
LEN has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $255.9M |
| Q2 2026 | $467.1M |
| Q1 2026 | $269.7M |
| Q4 2025 | $57,000 |
| Q3 2025 | $512.4M |
| Q2 2025 | $521.4M |
| Q1 2025 | $774.5M |
| Q4 2024 | $527.2M |
LEN spent $993M buying back its own shares over the past year, down 57% from the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -1.0x | Net Cash |
| Q4 2025 | 0.8x | Very low |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
LEN has more cash than debt.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
LEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.3 | Neutral |
| Stochastic | 69.2 | Neutral |
LEN's weekly RSI is 46 (neutral) and its Stochastic is 69 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
LEN PE vs Consumer Cyclical Sector
| Metric | LEN | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 12% below |
| PE % | 99 | 47 | 52 pts above |
LEN is trading at 16x earnings, a 12% discount to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
LEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $82.5 | 1.3% above |
| 20 week MA | $83.6 | 0% above |
| 50 week MA | $94.0 | 11% below |
| 100 week MA | $107.5 | 22% below |
| 200 week MA | $123.9 | 33% below |
LEN has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
LEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $56.0 | $80.4 | +44% |
| 2021 | $80.4 | $112.1 | +39% |
| 2022 | $112.1 | $90.6 | -19% |
| 2023 | $90.6 | $149.0 | +64% |
| 2024 | $149.0 | $137.2 | -8% |
| 2025 | $137.2 | $104.9 | -24% |
| 2026 YTD | $104.9 | $83.6 | -20% |
LEN has the edge over LCID on returns for 2026, with the stronger performance.